ArticleTranslational medicine @ UniSa2014
Anandamide inhibits breast tumor-induced angiogenesis.
Article in Translational medicine @ UniSa, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- The endocannabinoid system in cancer biology: a mini-review of mechanisms and therapeutic potential.Oncology reviews · 2025Review
- A Prospective Observational Study on the Role of Immunohistochemical Expression of Orphanin in Laryngeal Squamous Cell Carcinoma Recurrence.Journal of personalized medicine · 2023Article
- Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer.Nature communications · 2023Article
- Application of the neuropeptide NPVF to enhance angiogenesis and osteogenesis in bone regeneration.Communications biology · 2023Article
- Should oncologists trust cannabinoids?Frontiers in pharmacology · 2023Review
- A zebrafish HCT116 xenograft model to predict anandamide outcomes on colorectal cancer.Cell death & disease · 2022Article
- Cannabinoids as anticancer drugs: current status of preclinical research.British journal of cancer · 2022Review
- Anandamide-Modulated Changes in Metabolism, Glycosylation Profile and Migration of Metastatic Melanoma Cells.Cancers · 2022Article
- Cannabidiol (CBD) in Cancer Management.Cancers · 2022Review
- Cannabinoids, their cellular receptors, and effects on the invasive phenotype of carcinoma and metastasis.Cancer reports (Hoboken, N.J.) · 2022Review
- Proangiogenic Effect of Affinin and an Ethanolic Extract fromMolecules (Basel, Switzerland) · 2021Article
- Endocannabinoid System and Tumour Microenvironment: New Intertwined Connections for Anticancer Approaches.Cells · 2021Review
- Review
- Potentials of truffles in nutritional and medicinal applications: a review.Fungal biology and biotechnology · 2020Review
- Inner Engineering Practices and Advanced 4-day Isha Yoga Retreat Are Associated with Cannabimimetic Effects with Increased Endocannabinoids and Short-Term and Sustained Improvement in Mental Health: A Prospective Observational Study of Meditators.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Anti-tumour actions of cannabinoids.British journal of pharmacology · 2019Review
- Future Aspects for Cannabinoids in Breast Cancer Therapy.International journal of molecular sciences · 2019Review
- Insights into the effects of the endocannabinoid system in cancer: a review.British journal of pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most frequently diagnosed malignancies and a leading cause of cancer death in women. Great advances in the treatment of primary tumors have led to a significant increment in the overall survival rates, however recurrence and metastatic disease, the underlying cause of death, are still a medical challenge. Breast cancer is highly dependent on neovascularization to progress. In the last years several anti-angiogenic drugs have been developed and administered to patients in combination with chemotherapeutic drugs. Collected preclinical evidence has proposed the endocannabinoid system as a potential target in cancer. The endocannabinoid anandamide has been reported to affect breast cancer growth at multiple levels, by inhibiting proliferation, migration and invasiveness in vitro and in vivo and by directly inhibiting angiogenesis. Aim of the present work is to investigate if anandamide is able to affect the proangiogenic phenotype of the highly invasive and metastatic breast cancer cells MDA-MB-231. We found that following anandamide treatment, MDAMB-231 cells lose their ability to stimulate endothelial cells proliferation in vitro, due to a significant inhibition of all the pro-angiogenic factors produced by these cells. This finding adds another piece of evidence to the anti-tumor efficacy of anandamide in breast cancer.
Indexed as
Identifiers
25147760PMC4140423W2168919947What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.